The State Key Laboratory for Emerging Infectious Diseases at the University of Hong Kong (HKU) and the InnoHK Center for Virology, Vaccinology and Therapeutics (CVVT) have pioneered an influenza virus ...

The new nasal vaccine only needs one dose and produces reliable immunity right at the site where the virus enters the body.

How it works Convidencia is a viral vector vaccine using adenovirus five. With a viral vector, there is essentially a viral particle, which is programmed not to replicate. So, what is administered ...

GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations ...

Nasal Spray H5N1 Avian Influenza Vaccine Developed Apr. 8, 2025 — Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian ...

Dengue’s rise in 2024, influenced by climate change and shifting serotypes, underscores the need for effective vaccines to ...

The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a ...

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations 22.04.2025 / 15:07 CET/CEST The issuer is solely ...

Intranasal influenza virus-vectored vaccine offers protection against clade 2.3.4.4b H5N1 infection in small animal models. Nature Communications , 2025; 16 (1) DOI: 10.1038/s41467-025-58504-z ...